NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









OmniSpirant Therapeutics

OmniSpirant Therapeutics

Private
IrelandHealthcare & Life Scienceshttps://www.omnispirant.com/

Last Round

Seed

Jan 14, 2025

Total Funding Raised

$13.81M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

OmniSpirant Therapeutics is a biotechnology company developing a first-in-class regenerative gene therapy platform, 'OmniSomes', for RNA-based treatments targeting respiratory diseases and cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

exosome therapygene therapydrug delivery platformregenerative medicinecystic fibrosisstem cell exosomeslung cancerinhaled drug deliverynon-viral deliveryRNA deliveryrespiratory therapyextracellular vesiclespreclinical biotechAcute Respiratory Distress SyndromeARDS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

OmniSpirant Therapeutics Comparables

Compare OmniSpirant Therapeutics with similar companies based on industry and business-model similarity.

OmniSpirant Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

OmniSpirant Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJan 14, 2025
GrantFeb 14, 2023
GrantJun 1, 2022
GrantFeb 1, 2019

OmniSpirant Therapeutics Investors

Notable investors and investment history

OmniSpirant Therapeutics investors
InvestorRounds
European CommissionGrant
Emily's EntourageGrant
Horizon EuropeGrant
Cystic Fibrosis TrustGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 1, 2026

    Grew 30% QoQ from 10 to 13 employees.

  • May 1, 2025

    Monthly visitors increased 1258% MoM, from 19 to 258.

OmniSpirant Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

OmniSpirant Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about OmniSpirant Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersIreland
Employee Range14
Year Founded2016
Last FundingJan 14, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.